生物追踪器ASCO事件列表_60页_668kb
报告摘要
药物与疾病关联总结
核心内容概述
以下总结列出了2025年5月22日至6月3日期间，针对不同癌症及疾病类型的药物研究或治疗活动。文档以表格形式呈现，包含疾病名称和对应的药物名称，主要涵盖血液系统恶性肿瘤、实体瘤及其他特定疾病。
主要观点
- 药物研发和临床试验活动集中在多种癌症类型上，包括但不限于白血病、淋巴瘤、乳腺癌、肺癌、前列腺癌等。
- 同一疾病可能涉及多个药物，显示该领域存在多种治疗策略和研究方向。
- 有些药物在多个疾病类别中被提及，可能具有广谱抗肿瘤活性或用于联合治疗。
关键信息汇总
急性淋巴细胞白血病 (ALL)
- Aucatzyl (2025-06-01)
- Iclusig (2025-05-30)
急性髓系白血病 (AML)
- Ziftomenib (2025-06-02)
- Lisaftoclax (2025-06-02)
- Rezlidhia (2025-06-01)
- FP-1305 (2025-05-30)
- RC1012 (2025-05-30)
- ICT01 (2025-05-22)
- Inqovi (2025-05-22)
- Azacitidine (2025-05-22)
阿尔茨海默病相关淀粉样蛋白 (AL) 淀粉样变性
- NXC-201 (2025-06-03)
肛门癌
- Zynyz (2025-05-31)
淋巴瘤 (AITL)
- GNTbm-38 (2025-05-22)
胆道癌
- Ziihera (2025-05-31)
- FF-10832 (2025-05-31)
膀胱癌
- Zelenectide Pevedotin (2025-06-02)
- Keytruda (2025-06-02, 2025-06-01)
- Opdivo (2025-06-02, 2025-06-01)
- Padcev (2025-06-02)
- M6223 (2025-06-01)
- Imfinzi (2025-06-01)
- Bavencio (2025-06-01)
- Trodelvy (2025-06-01)
- Yervoy (2025-06-01)
- VesiGel (2025-06-02)
- BH011 (2025-06-02)
BPDCN（浆细胞样树突状细胞肿瘤）
- Elzonris (2025-06-01)
- Pivekimab (2025-05-27)
骨相关疾病（包括骨转移）
- SHR-2017 (2025-06-02)
脑癌（恶性胶质瘤、胶质母细胞瘤）
- ONC201 (2025-06-02)
- KROS-101 (2025-06-02)
- IL13 Ra2 CAR-T Program (Tmunity) (2025-06-01)
- ST101 (Sapience) (2025-05-31)
- Azeliragon (2025-05-31)
- Ojemda (2025-05-31)
- INB-200 (2025-05-30)
- BXQ-350 (2025-05-30)
- IVS-1001 (2025-05-30)
- Dubodencel (2025-05-30)
- Pemazyre (2025-05-30)
- Anlotinib (2025-05-30)
乳腺癌（HER2+）
- Herceptin (2025-06-02)
- Tykerb (2025-06-02)
- Nolvadex (2025-06-02)
- BI-1810631 (2025-06-02)
- Enhertu (2025-06-02)
- Patritumab Deruxtecan (2025-05-30)
前列腺癌
- Zytiga (2025-06-03)
- Nubeqa (2025-06-03)
- Xtandi (2025-06-03, 2025-06-02)
- CAN-2409 (2025-06-03)
- Akeega (2025-06-03)
- Rubraca (2025-06-02)
- Pluvicto (2025-06-02)
- 64Cu-SAR-bisPSMA (2025-06-02)
- Xofigo (2025-05-28)
肺癌（未指定）
- VGT-309 (2025-06-02)
胃癌
- Disitamab Vedotin (2025-06-02)
- Ziihera (2025-06-02)
- Imfinzi (2025-06-01)
- Utidelone (2025-05-31)
- Enhertu (2025-05-31)
- TST-001 (2025-05-31)
- Satri-cel (2025-05-31)
- Lenvima (2025-05-31)
- Keytruda (2025-05-31)
- Venadaparib (2025-05-31)
- LB1908 (2025-05-31)
- Hercesi (2025-05-30)
- Eniluracil (2025-05-30)
- Fruzaqla (2025-05-30)
- IMC001 (Immunofoco) (2025-05-30)
- IMC-002 (2025-06-02)
- CS1002 (2025-05-31)
胃肠道间质瘤 (GIST)
- Mektovi (2025-05-31)
移植物抗宿主病 (GVHD)
- SER-155 (2025-05-27)
头颈癌
- Versamune-HPV (2025-06-02)
- Kadcyla (2025-06-02)
- CUE-101 (2025-06-02)
- PF-08046054 (2025-06-02)
- Ozuriftamab Vedotin (2025-06-02)
- ficerafusp alfa (2025-06-01)
- Pepinemab (2025-06-01)
- Opdivo (2025-06-01)
- TG4050 (2025-06-01)
- Keytruda (2025-06-01)
- Evorpacept (2025-05-30)
- CUE-101 (2025-05-30)
- Petosemtamab (2025-05-22)
- Versamune-HPV (2025-05-22)
- ficerafusp alfa (2025-05-22)
- BI 765063 (2025-05-22)
- BI 754091 (2025-05-22)
血液系统癌症
- LB1410 (2025-06-02)
- Mesutoclax (2025-06-01)
- Purinostat Mesylate (2025-06-01)
- XNW5004 (2025-05-31)
肝细胞癌 (HCC)
- IMC-002 (2025-06-02)
- CS1002 (2025-05-31)
- Keytruda (2025-05-31)
- Imfinzi (2025-05-31)
- VG-161 (2025-05-30)
- BST02 (2025-05-30)
淋巴瘤（惰性非霍奇金）
- Breyanzi (2025-06-01)
白细胞减少症/中性粒细胞减少症
- Ryzneuta (2025-05-30)
脂肪肉瘤
- Ibrance (2025-05-31)
未指定的软组织肉瘤
- Anlotinib (2025-06-01)
- Loqtorzi (2025-05-31)
实体瘤
- CTS2190 (2025-06-02)
- Rubraca (2025-06-02)
- Sigvotatug Vedotin (2025-06-02)
- emiltatug ledadotin (2025-06-02)
- HSK42360 (2025-06-02)
- BRY812 (2025-06-02)
- ZGGS-15 (2025-06-02)
- BAT8008 (2025-06-02)
- SAR-445877 (2025-06-02)
- GT201 (2025-06-02)
- MRTX1719 (2025-06-02)
- A2B694 (2025-06-02)
- HLX-301 (2025-06-02)
- SPYK04 (2025-06-02)
- VB10.NEO (2025-06-02)
- Hansizhuang (2025-06-02)
- Voyager-V1 (2025-06-02)
- AdAPT 001 (2025-06-02)
- Vitrakvi (2025-06-02)
- OMX-0407 (2025-06-02)
- adrixetinib (2025-06-02)
- Zurletrectinib (2025-06-02)
- S-531011 (2025-06-02)
- ESG-401 (2025-06-02)
- cafelkibart (2025-06-02)
- CBL0137 (2025-05-31)
- CJRB-101 (2025-05-31)
- EP0031 (2025-05-31)
- Volrustomig (2025-05-31)
- Vilastobart (2025-05-31)
- RYB-001 (2025-05-30)
- RS-0139 (2025-05-30)
- JS-014 (2025-05-30)
- HX008 (2025-05-30)
- INCB99280 (2025-05-30)
- TQB-2102 (2025-05-30)
- Utidelone (2025-05-30)
- Iza-bren (2025-05-30)
- HF158K1 (2025-05-30)
- SYN-27M (2025-05-30)
- RBS-2418 (2025-05-30)
- JSKN016 (2025-05-30)
- ACE-86225106 (2025-05-30)
- C-019199 (2025-05-30)
- Cesium-131 (2025-05-30)
- TAC01-CLDN18.2 (2025-05-30)
- GT101 (2025-05-30)
- GH21 (2025-05-30)
- TT125-802 (2025-05-30)
- Zurletrectinib (2025-05-30)
- MK-1084 (2025-05-30)
- Voyager-V1 (2025-05-30)
- Patritumab Deruxtecan (2025-05-30)
- ATT-11T (2025-05-30)
阴道癌
- Cadonilimab (2025-06-03)
- BAT 1308 (2025-06-02)
- TG4001 (2025-06-02)
- VB10.16 (2025-06-01)
- Loqtorzi (2025-06-01)
- SG001 (2025-06-01)
- ATG-008 (2025-05-23)
骨髓增生异常综合征 (MDS)
- Rytelo (2025-06-01)
- Reblozyl (2025-05-30)
- FP-1305 (2025-05-30)
- IMM01 (2025-05-30)
- Rytelo (2025-05-28)
- Lisaftoclax (2025-05-22)
- Azacitidine (2025-05-22)
骨髓纤维化 (MF)
- Jaktinib (2025-06-01)
- Jakafi (2025-06-01)
- RyteLO (2025-05-28)
鼻咽癌
- TQB-2618 (2025-06-02)
- LBL-007 (2025-06-02)
- HBM9167 (2025-05-31)
神经母细胞瘤
- Ifinwil (2025-05-31)
神经内分泌瘤 (NET)
- Cabometyx (2025-06-02)
- ZG-006 (2025-05-31)
- LBL-024 (2025-05-31)
- ZG-005 (2025-05-30)
- ZG-006 (2025-05-30)
- VMT-α-NET (2025-05-30)
- Obrixtamig (2025-05-22)
神经纤维瘤病 (NF)
- Koselugo (2025-06-02)
- FCN-159 (2025-05-31)
非霍奇金淋巴瘤 (NHL)
- HCB101 (2025-06-02)
- IMM-0306 (2025-06-01)
- ICP-B05 (2025-06-01)
- SHR-A1921 (2025-05-31)
- CA-4948 (2025-05-31)
- XNW5004 (2025-05-31)
非小细胞肺癌 (NSCLC)
- IBI-363 (2025-06-03)
- Olomorasib (2025-06-02)
- Tagrisso (2025-06-02)
- AFM24 (2025-06-02)
- Teliso-V (2025-06-02)
- KB707 (2025-06-02)
- APL-502 (2025-06-02)
- Lumakras (2025-06-02)
- JIN-A02 (2025-06-01)
- APL-502 (2025-06-01)
- Orpathys (2025-06-01)
- Imfinzi (2025-06-01)
- Krazati (2025-06-01)
- Patritumab Deruxtecan (2025-06-01)
- Datroway (2025-06-01)
- Sevabertinib (2025-06-01)
- Sacituzumab Tirumotecan (2025-06-01)
- Lorbrena (2025-05-31)
- Opdivo (2025-05-31)
- Trodelvy (2025-05-31)
- Opdualag IV (2025-05-31)
- MYTX-011 (2025-05-31)
- THIO (2025-05-31)
- APL-101 (2025-05-31)
- Dovbleron (2025-05-31)
- HX-009 (2025-05-30)
- GT101 (2025-05-30)
- GH21 (2025-05-30)
- TT125-802 (2025-05-30)
- ZG-005 (2025-05-30)
- TQB-2102 (2025-05-30)
- Utidelone (2025-05-30)
- Iza-bren (2025-05-30)
- HF158K1 (2025-05-30)
- SYN-27M (2025-05-30)
- RBS-2418 (2025-05-30)
- JSKN016 (2025-05-30)
- ACE-86225106 (2025-05-30)
- C-019199 (2025-05-30)
- Cesium-131 (2025-05-30)
- TAC01-CLDN18.2 (2025-05-30)
卵巢癌
- INCB123667 (2025-06-03)
- Zotatifin (2025-06-03)
- BAT-8006 (2025-06-03)
- IBI354 (2025-06-02)
- ERNA-101 (2025-06-02)
- Relacorilant (2025-06-02)
- Jemperli (2025-06-02)
- CPI-0209 (2025-06-02)
- CUSP06 (2025-06-02)
- MK-4830 (2025-06-01)
- JIN-A02 (2025-06-01)
- APL-502 (2025-06-01)
- Orpathys (2025-06-01)
- GT307 (2025-06-01)
- JSKN003 (2025-06-01)
- Relatlimab (2025-06-01)
- Ceralasertib (2025-06-01)
- ZG-005 (2025-06-01)
- TAK-676 (2025-06-01)
- SHR-A1811 (2025-06-01)
- Adcetris (2025-06-01)
- GT316 (2025-06-01)
- Gotistobart (2025-06-01)
胰腺癌
- ADC-1013 (2025-06-02)
- Pelareorep (2025-06-02)
- IBI-343 (2025-06-02)
- Tedopi (2025-06-02)
- Aldoxorubicin (2025-06-02)
- EBC-129 (2025-06-02)
- Anktiva (2025-06-02)
- TQB-2868 (2025-05-31)
- GP-2250 (2025-05-31)
- Onivyde (2025-05-31)
- Elraglusib (2025-05-31)
- Optune Lua (2025-05-31)
- Surufatinib (2025-05-31)
- Trodelvy (2025-05-31)
- Keytruda (2025-05-31)
- Datroway (2025-05-31)
- Stivarga (2025-05-31)
- IN-10018 (2025-05-31)
- Andatinib (2025-05-31)
- Rybrevant (2025-05-31)
- Iza-bren (2025-05-30)
- RS-0139 (2025-05-30)
- MT-302 (2025-05-30)
- JS-014 (2025-05-30)
- HX008 (2025-05-30)
- INCB99280 (2025-05-30)
- TQB-2102 (2025-05-30)
- Utidelone (2025-05-30)
- Fruzaqla (2025-05-30)
- C-019199 (2025-05-30)
- Cesium-131 (2025-05-30)
- TAC01-CLDN18.2 (2025-05-30)
骨肉瘤
- ALMB-0168 (2025-06-02)
卵巢癌
- INCB123667 (2025-06-03)
- Zotatifin (2025-06-03)
- BAT-8006 (2025-06-03)
- IBI354 (2025-06-02)
- ERNA-101 (2025-06-02)
- Relacorilant (2025-06-02)
- Jemperli (2025-06-02)
- CPI-0209 (2025-06-02)
- CUSP06 (2025-06-02)
- MK-4830 (2025-06-01)
- JIN-A02 (2025-06-01)
- APL-502 (2025-06-01)
- Orpathys (2025-06-01)
- GT307 (2025-06-01)
- JSKN003 (2025-06-01)
- Relatlimab (2025-06-01)
- Ceralasertib (2025-06-01)
- ZG-005 (2025-06-01)
- TAK-676 (2025-06-01)
- SHR-A1811 (2025-06-01)
- Adcetris (2025-06-01)
- GT316 (2025-06-01)
- Gotistobart (2025-06-01)
多发性骨髓瘤 (MM)
- Darzalex Faspro (2025-06-03)
- Sarclisa (2025-06-03)
- Elrexfio (2025-06-03)
- Carvykti (2025-06-03)
- JNJ-79635322 (2025-06-03)
- Sarclisa (2025-06-02)
- Blenrep (2025-06-02)
- Ogsiveo (2025-06-02)
- Talvey (2025-06-01)
- Elrexfio (2025-06-01)
- TASQ (2025-06-01)
- Iberdomide (2025-06-01)
- Blenrep (2025-06-01)
- Sarclisa (2025-06-01)
- Blenrep (2025-06-01)
- Carvykti (2025-06-01)
- BMS-986393 (2025-06-01)
- Blenrep (2025-06-01)
- Darzalex Faspro (2025-06-01)
- Kyprolis (2025-06-01)
- Lynozyfic (2025-05-22)
小细胞肺癌 (SCLC)
- ZL-1310 (2025-06-02)
- Zepzelca (2025-06-02)
- 7MW3711 (2025-06-02)
- ZG-006 (2025-06-02)
- Imdelltra (2025-06-02)
- Tecentriq (2025-06-02)
- Imfinzi (2025-06-01)
- Zepzelca (2025-06-01)
- Hansizhuang (2025-05-31)
- LB2102 (2025-05-31)
- Obrixtamig (2025-05-31)
- Debio 0123 (2025-05-31)
- HTMC-0435 (2025-05-31)
妇科肿瘤
- INCB123667 (2025-06-03)
- Zotatifin (2025-06-03)
- BAT-8006 (2025-06-03)
- IBI354 (2025-06-02)
- ERNA-101 (2025-06-02)
- Relacorilant (2025-06-02)
- Jemperli (2025-06-02)
- CPI-0209 (2025-06-02)
- CUSP06 (2025-06-02)
- MK-4830 (2025-06-01)
- JIN-A02 (2025-06-01)
- APL-502 (2025-06-01)
- Orpathys (2025-06-01)
- GT307 (2025-06-01)
- JSKN003 (2025-06-01)
- Relatlimab (2025-06-01)
- Ceralasertib (2025-06-01)
- ZG-005 (2025-06-01)
- TAK-676 (2025-06-01)
- SHR-A1811 (2025-06-01)
- Adcetris (2025-06-01)
- GT316 (2025-06-01)
- Gotistobart (2025-06-01)
肾癌
- Cabometyx (2025-06-02)
- Fotivda (2025-06-02)
- CBM588 (2025-06-02)
- APL-502 (2025-06-02)
- Tecentriq (2025-06-02)
- NDI-101150 (2025-06-02)
- Opdivo (2025-06-01)
- ALLO-316 (2025-06-01)
- Casdatifan (2025-06-01)
- Casdatifan (2025-05-31)
- Keytruda (2025-05-31)
乳腺癌（HR+/HER2-）
- Bria-IMT (2025-06-03)
- RLY-2608 (2025-06-02)
- TQB-2930 (2025-06-02)
- Giredestrant (2025-06-02)
- RLY-2608 (2025-06-02)
- Imlunestrant (2025-06-02)
- Orserdu (2025-06-02)
- Kisqali (2025-06-02)
- Ibrance (2025-06-02)
- Verzenio (2025-06-02)
- Orserdu (2025-06-02)
- Vosilasarm (2025-06-02)
- Giredestrant (2025-06-02)
- RLY-2608 (2025-06-02)
- Imlunestrant (2025-06-02)
- Itovebi (2025-05-31)
- Enhertu (2025-05-31)
- Itovebi (2025-05-31)
- Vepdegestrant (2025-05-31)
- Epacadostat (2025-05-30)
- Xuanyuening (2025-05-30)
- PF-07248144 (2025-05-30)
- DZD-6008 (2025-05-26)
- 7MW3711 (2025-05-23)
- Sacituzumab Tirumotecan (2025-05-23)
- Sacituzumab Tirumotecan (2025-05-23)
- HBM9167 (2025-05-23)
- Gavreto (2025-05-22)
- Zipalertinib (2025-05-22)
- BI-1810631 (2025-05-22)
- AVC-S-101, Avidicure (2025-05-22)
多发性骨髓瘤 (MM)
- Darzalex Faspro (2025-06-03)
- Sarclisa (2025-06-03)
- Elrexfio
展开完整摘要
试读结束，高清完整版pdf/doc/ppt,请点下载
